WO1989011859A1 - Pharmaceutical compositions and use thereof in treating inflammation - Google Patents
Pharmaceutical compositions and use thereof in treating inflammation Download PDFInfo
- Publication number
- WO1989011859A1 WO1989011859A1 PCT/GB1989/000638 GB8900638W WO8911859A1 WO 1989011859 A1 WO1989011859 A1 WO 1989011859A1 GB 8900638 W GB8900638 W GB 8900638W WO 8911859 A1 WO8911859 A1 WO 8911859A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cbg
- inflammatory agent
- composition
- glucocorticoid
- inflammation
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 31
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 31
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 9
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 45
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 45
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 239000003862 glucocorticoid Substances 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 39
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 18
- 101000868967 Homo sapiens Corticosteroid-binding globulin Proteins 0.000 claims description 14
- 102000049531 human SERPINA6 Human genes 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 229960000890 hydrocortisone Drugs 0.000 claims description 9
- 241000894007 species Species 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 241000282412 Homo Species 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229940102223 injectable solution Drugs 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 101710116773 Corticosteroid-binding globulin Proteins 0.000 claims 8
- VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 claims 2
- 229960004584 methylprednisolone Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 1
- 102000014034 Transcortin Human genes 0.000 abstract 2
- 108010011095 Transcortin Proteins 0.000 abstract 2
- 101710175199 Corticosteroid-binding protein Proteins 0.000 description 88
- 230000027455 binding Effects 0.000 description 22
- 108010067372 Pancreatic elastase Proteins 0.000 description 15
- 102000016387 Pancreatic elastase Human genes 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 150000003431 steroids Chemical class 0.000 description 12
- 229940037128 systemic glucocorticoids Drugs 0.000 description 10
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 108010028275 Leukocyte Elastase Proteins 0.000 description 5
- 102000016799 Leukocyte elastase Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000002411 adverse Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108090000617 Cathepsin G Proteins 0.000 description 1
- 102000004173 Cathepsin G Human genes 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 150000001883 corticosterone derivatives Chemical class 0.000 description 1
- 150000001885 cortisol derivatives Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- -1 for example Proteins 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000022558 protein metabolic process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000013606 secretion vector Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to anti-inflammatory agents such as glucocorticoids and their use in treating inflammation.
- Glucocorticoids are steroid hormones, many of which are potent anti-inflammatory agents. Their physiological effects are not limited to their * anti-inflammatory properties, however, nor are their effects restricted specifically to inflamed tissue. Protein, lipid and carbohydrate metabolism can be altered adversely and electrolyte balance can be disturbed, particularly when large or repeated therapeutic doses of the anti-inflammatory glucocorticoids are administered.
- Certain recently developed synthetic glucocorticoids show promise as therapeutic alternatives to the natural anti-inflammatory glucocorticoids such as cortisone, cortisol and corticosterone.
- the synthetic analogues which include dexamethasone and beta ethasone, exhibit reduced effects on electrolyte balance and tend therefore to elicit fewer adverse side effects. In many instances, they also exhibit greater potency as anti-inflammatory agents relative to their natural counterparts. The greater potency of the synthetic analogues is believed to ste , in part, from their reduced affinity for binding to the plasma protein known as corticosteroid binding protein (CBG) .
- CBG corticosteroid binding protein
- glucocorticoids Apart form the numerous physiological effects exerted by glucocorticoids, their use in treating inflammation is further complicated by their ability to affect a broad range of tissues, whether inflamed or healthy. Because so many tissues are responsive to such steroids, they are rarely administered systemically unless inflammation is particularly severe or life threatening.
- a pharmaceutical composition useful in treating inflammation in a mammal which comprises CBG, an anti-inflammatory agent which binds therewith, and a pharmaceutically acceptable carrier.
- Any anti-inflammatory agent which binds with appropriate affinity to CBG may be used in the present composition.
- the anti-inflammatory agent is present in an amount sufficient to bind substantially all of the CBG present in the composition.
- the anti-inflammatory agent is a glucocorticoid.
- the amount of anti- inflammatory agent required in the present composition is less than that required in the absence of CBG since, as will be explained, CBG is capable of localizing the effects of the anti-inflammatory agent to an inflammation site.
- a method for treating inflammation in a mammal which comprises administering thereto a pharmaceutical composition comprising CBG-bound anti- inflammatory agent.
- CBG-bound glucocorticoids can be released form CBG at local sites of inflammation by the action of leukocyte elastase, an enzyme which is prevalent at sites of inflammation.
- Leukocyte elastase specifically cleaves the CBG component of the glucocorticoid:CBG complex, allowing glucocorticoid to dissociate from CBG and exert its anti-inflammatory action directly at the inflammation site.
- glucocorticoid in CBG-bound form is an effective means for localizing glucocorticoid effects to those tissues or sites at which inflammation is active, thus reducing the indiscriminate stimulation of other tissues by glucocorticoids which results in undesirable side effects.
- any anti-inflammatory agent which binds with CBG can be targeted for release specifically at an inflammation site by administering that particular agent in CBG-bound form i.e. as a CBG:anti-inflammatory agent complex.
- CBG is cleaved specifically by leukocyte elastase, a serine protease released locally by neutrophils at sites of inflammation, is particularly remarkable.
- the region of the CBG molecule that contains the elastase binding site is not well conserved by comparison with another well known elastase substrate, ⁇ : -antitrypsin.
- the elastase cleavage site on CBG involves a neighboring glycosylation site not present at the elastase cleavage site on _.- antitrypsin.
- CBG is indeed cleaved by leucocyte elastase. Moreover, it has been found that steroid binding affinity of CBG is substantially lost following CBG cleavage by leukocyte elastase.
- anti-inflammatory agents which bind with CBG are administered in CBG-bound form to treat inflammation in mammals.
- binding of a particular anti- inflammatory and CBG is mediated by the affinity of one molecule for the other and not through a physical link such as a covalent bond or chemical linking agent.
- the degree of affinity between CBG and the selected anti-inflammatory agent should be sufficient to enable CBG and the anti- inflammatory agent to remain in association following administration thereof to the mammal to be treated, and allow the agent to dissociate following elastase-induced cleavage of CBG at an inflammation site.
- Anti-inflammatory agents suitable for use in the present invention may be identified by screening anti- inflammatory agents in a CBG-binding assay and selecting those having suitable CBG-binding affinity.
- an anti-inflammatory agent having a CBG affinity constant (dissociation rate, Kd) within the range from 0.1 to 10 nanomolar at about 4'C and physiological pH is suitable for use with CBG according to the present invention.
- Kd dissociation rate
- a protocol for screening anti-inflammatory agents for suitability in the present context is described by Mickelson et al. , supra, incorporated herein by reference, which allows the binding affinity of a selected steroid for CBG to be compared with the affinity of human CBG for one of its natural ligands, cortisol.
- any anti-inflammatory agent having CBG human binding affinity which approximates that of cortisol (0.7 nanomolar under the conditions noted above) is preferred for use in accordance with the present invention.
- Mickelson et al., supra. also identify some criteria useful in predicting whether a particular steroid will be capable of binding adequately with human CBG such as the presence of a 3-oxo group and the absence of an 11 ⁇ -hydroxy group on the steroid. While these criteria can be useful in determining binding affinity of steroid for human CBG, it should be understood that the determinative measure of suitability of anti-inflammatory agent, whether steroidal in structure or not, is stability of the CBG:selected agent complex, under the conditions noted above.
- Specific anti-inflammatory agents useful herein include corticosteroids having glucocorticoid activity such as cortisol and other natural, anti-inflammatory ligands of CBG such as corticosterone and cortisone.
- corticosteroids having glucocorticoid activity such as cortisol and other natural, anti-inflammatory ligands of CBG such as corticosterone and cortisone.
- Synthetic glucocorticoids which exhibit reduced adverse effects on electrolyte balance, such as prednisolone and ethylprednisolone may also be used.
- synthetic corticosteroids developed subsequently or natural corticosteroids discovered hereafter are useful provided, of course, that they exhibit anti- inflammatory activity and an appropriate CBG binding affinity.
- the anti-inflammatory agent used in the pharmaceutical compositions of the invention should be of pharmaceutical grade. Whereas acid- and base-addition glucocorticoid salts are commonly employed in prior art compositions to enhance solubility of the glucocorticoid, in injectable solutions for example, salt forms of the selected glucocorticoid are not required in the present compositions although they may be used, if desired. When complexed with CBG, glucocor ⁇ ticoids are sufficiently soluble in solution in the amounts useful to treat inflammation, although solubilizers standard in the protein formulation art, such as mannitol, may be used.
- CBG useful in the composition of the invention is now a well characterized protein, having been identified in human plasma over thirty years ago. It has since been identified in virtually every vertebrate species examined and has been isolated from numerous mammalian species including rabbit, guinea pig, rodent, humans and others (for a review see Brien, Clinical Endocrinology (1981) 14, 193- 212) .
- CBG may be isolated from"serum using techniques now well known in the art. The most practical and efficient of these techniques involve the use of affinity columns in which the immobilized ligand is either a glucocorticoid or a derivative thereof which binds with high affinity to CBG. The preparation of such a column, in which a cortisol derivative is cross-lined on Sepharose, and its use. in isolating CBG are described by
- Antibodies to CBG have also now been prepared (see Robinson et al. , supra) and may also be used to generate an affinity column useful to isolate CBG from serum.
- compositions of the present invention may be prepared using recombinant CBG i.e. CBG that is produced by microbial cells genetically engineered for this purpose.
- CBG recombinant CBG
- DNA coding for the amino acid sequence thereof is incorporated on any of the well-known expression or secretion vectors.
- the resulting DNA construct is then introduced into the microbial host for which the selected vector is adapted, the host is cultured under conditions conducive to expression of the CBG-encoding DNA and the CBG so produced is recovered, using purification techniques similar to those used to recover naturally occurring CBG.
- the CBG-encoding DNA to be incorporated on the selected vector may be obtained using any of a variety of techniques used commonly in the genetic engineering art, such as by synthesis or by isolating cDNA from a human liver or lung cDNA library e.g. in the manner reported by Hammond et al. in INSERM. Vol 149, 113-121, 1986.
- the CBG-encoding DNA is then incorporated on the expression vector i.e. is linked operably to expression control DNA sequences, including transcription-promoting and terminating sequences and optionally including sequences enabling the CBG product to be secreted to the medium following its expression.
- Numerous expression vectors are available for use with a variety of microbial hosts, such as bacteria including E. coli.
- CBG Stre ⁇ tomyces and Bacillus subtilis and eukaryotes including yeasts such as Saccharomvces and Candida filamentous fungi such as the nidulans, nicer and orvzae species of Asper ⁇ illus. and mammalian cell lines such as COS and CHO.
- yeasts such as Saccharomvces and Candida filamentous fungi such as the nidulans, nicer and orvzae species of Asper ⁇ illus.
- mammalian cell lines such as COS and CHO.
- recombinant CBG may be produced using vector systems and protocols already established for use with these hosts.
- CBG obtained from any source may be used provided that it has the appropriate binding affinity for the selected glucocorticoid and is susceptible to cleavage by elastase. Since it is conceivable that a CBG:elastase relationship exists which is specific for a given mammalian species, it is recommended that the administered composition comprises CBG native to the mammalian species, being treated.
- human CBG is preferably used in compositions administered to treat inflammation in humans, equine CBG is used in compositions intended for treating inflammation in horses, etc.
- the CBG binding affinity of a particular anti-inflammatory agent may vary, depending on the mammalian source of the CBG selected. Accordingly, binding assays of the type described above should be performed in order to select those anti- inflammatory agents most suitable for use in combination with a given CBG species.
- compositions of the invention the selected anti-in lammatory agent and CBG are simply mixed in solution, such as physiological saline, at pH 7.5, with agitation to generate the required complexes. Formation of CBG:anti-inflammatory agent complexes can be facilitated by incubating the mixture at physiological temperature and pH. It is important, when CBG:glucocorticoid complexes are prepared, to maintain pH above 6, preferably above pH 6.5. The affinity of CBG for glucocorticoid can be reduced below pH 6, and the protein may be irreversibly denatured. It is desirable, in order to achieve the maximum localizing effect conferred by CBG following administration, that the CBG in the administered composition is saturated with glucocorticoid i.e.
- the molar ratio of glucocorticoid bound to CBG in the composition is substantially 1:1.
- a molar excess of glucocorticoid such as a molar ratio of from about 1.1:1 to about 5:1 (glucocorticoid:CBG) when generating the complexed material.
- Unbound glucocorticoid may remain with the complexed material, if desired, and can in fact be advantageous to ensure that saturation of CBG is maintained after administration and equilibration with endogenous steroid.
- CBG-bound glucocorticoid for administration, any of the conventional pharmaceutically acceptable carriers may be used, selection of which depends on the intended mode of administration and is dictated to some extent by the proteinaceous nature of the complexes.
- injectable solutions may be prepared by mixing CBG and anti- inflammatory agent in the presence of pharmaceutically acceptable liquid vehicles such as buffered saline and physiological saline.
- Compositions for topical application may be prepared as creams, lotions or ointments by incorporating the CBG-complexed agents in an appropriate base such as triglycerides. Surface active agents may also be used as may preservatives to prevent microbial growth over prolonged storage periods.
- Aerosol inhalable formulations of CBG-bound glucocorticoid may also be prepared using propellant and an appropriate liquid vehicle.
- compositions of the invention are useful in pharmaceutical and in veterinary applications to treat a variety of conditions involving inflammation. It will be appreciated that the compositions are particularly better adapted for systemic administration than known compositions comprising free anti-inflammatory agent since CBG-binding thereof is capable, by the limiting of therapeutic action to an inflammation site, of reducing the potential for adverse flucocorticoid effects elsewhere in the body. Because of the effect which CBG has on controlling release of glucocorticoid, for example, it may be used in the present compositions in lower amounts relative to compositions of flucocorticoid per se. to elicit an anti- inflammatory response.
- formulations When administered systemically as an injectable solution, formulations will comprise glucocorticoid (as CBG-bound glucocorticoid) generally in amounts equal to or less than amounts normally used in treating a particular medical condition.
- glucocorticoid as CBG-bound glucocorticoid
- formulations will comprise glucocorticoid (as CBG-bound glucocorticoid) generally in amounts equal to or less than amounts normally used in treating a particular medical condition.
- glucocorticoid as CBG-bound glucocorticoid
- formulations will comprise glucocorticoid (as CBG-bound glucocorticoid) generally in amounts equal to or less than amounts normally used in treating a particular medical condition.
- Pharmacopoeias such as Martindale, The Extra Pharmacopoeia Ed, J. E. F. Reynolds, The Pharmaceutical Press, London, 1982 (see particularly pp. 446-485) .
- CBG- bound anti-inflammatory agent will be useful to treat blood disorders including auto-immune haemolytic anemia, idiopathic thrombocytopenic purpura, arthritis, septicemia, etc.
- -Local injection may be appropriate to treat collagen and rheumatoid disorders as well as certain connective tissue disorders.
- the compositions may be applied to treat inflammation active at exposed areas of the skin. Topical formulations may be applied to open wounds to reduce inflammation.
- compositions of the invention will be useful to reduce inflammation in areas where the CBG-c ⁇ rticosteroid complexes can become exposed, following administration, to the action of leukocyte elastase.
- the steroid binding properties of human CBG were also tested using a cortisol binding capacity assay (Hammond and Lahteenmaki (1982) Clin. Chem. Acta 132:101) before and after a standard incubation with elastase, as described above. In this way it could be shown that >95% of the steroid binding activity of human CBG was lost after treatment with elastase, indicating that CBG had substantially lost its binding affinity for the anti- inflammatory agent cortisol following exposure to elastase.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Inflammation in mammals is treated by administering anti-inflammatory agent complexed with corticosteroid binding globulin (CBG).
Description
Pharmaceutical Compositions and Use Thereof in Treating Inflammation
Field of the Invention
This invention relates to anti-inflammatory agents such as glucocorticoids and their use in treating inflammation.
Background of the Invention
Glucocorticoids are steroid hormones, many of which are potent anti-inflammatory agents. Their physiological effects are not limited to their * anti-inflammatory properties, however, nor are their effects restricted specifically to inflamed tissue. Protein, lipid and carbohydrate metabolism can be altered adversely and electrolyte balance can be disturbed, particularly when large or repeated therapeutic doses of the anti-inflammatory glucocorticoids are administered.
Certain recently developed synthetic glucocorticoids show promise as therapeutic alternatives to the natural anti-inflammatory glucocorticoids such as cortisone, cortisol and corticosterone. The synthetic analogues, which include dexamethasone and beta ethasone, exhibit reduced effects on electrolyte balance and tend therefore to elicit fewer adverse side effects. In many instances, they also exhibit greater potency as anti-inflammatory agents relative to their natural counterparts. The greater potency of the synthetic analogues is believed to ste , in part, from their reduced affinity for binding to the plasma protein known as corticosteroid binding protein (CBG) . It has been reported that natural glucocorticoids become biologically inactivaced upon binding with CBG in the circulation whereas many synthetic
glucocorticoids either do not bind or bind poorly, and thus remain in free and active form (see Mickelson et al. , Biochemistry 1981, 2_0, 6211-6218 where binding affinities for some natural and synthetic glucocorticoids relative to CBG are tabled) . The capacity of synthetic glucocorticoids to escape CBG-binding and thus to remain free and biologically active following administration is presumed to be at least partly responsible for their enhanced anti- inflammatory properties in vivo. Apart form the numerous physiological effects exerted by glucocorticoids, their use in treating inflammation is further complicated by their ability to affect a broad range of tissues, whether inflamed or healthy. Because so many tissues are responsive to such steroids, they are rarely administered systemically unless inflammation is particularly severe or life threatening.
Summary of the Invention
It is therefore an object of the present invention to provide a strategy useful therapeutically for localizing the effects of anti-inflammatory agents, such as the glucocorticoids, predominantly to a site of inflammation. In accomplishing this object, there is provided, in accordance with one aspect of the invention, a pharmaceutical composition useful in treating inflammation in a mammal which comprises CBG, an anti-inflammatory agent which binds therewith, and a pharmaceutically acceptable carrier. Any anti-inflammatory agent which binds with appropriate affinity to CBG may be used in the present composition. Preferably, the anti-inflammatory agent is present in an amount sufficient to bind substantially all of the CBG present in the composition. In one preferred embodiment of the invention, the anti-inflammatory agent is a glucocorticoid. Generally, the amount of anti- inflammatory agent required in the present composition is
less than that required in the absence of CBG since, as will be explained, CBG is capable of localizing the effects of the anti-inflammatory agent to an inflammation site.
In accordance with another aspect of the invention, there is provided a method for treating inflammation in a mammal which comprises administering thereto a pharmaceutical composition comprising CBG-bound anti- inflammatory agent.
Detailed Description of the Preferred Embodiments
It has now been found that the binding affinity of CBG for such anti-inflammatory agents as the glucocorticoids can be exploited to improve upon their therapeutic effec¬ tiveness as anti-inflammatory agents even though such agents are thought to be rendered biologically inactive when bound by CBG. More particularly, it has been found that CBG-bound glucocorticoids can be released form CBG at local sites of inflammation by the action of leukocyte elastase, an enzyme which is prevalent at sites of inflammation. Leukocyte elastase specifically cleaves the CBG component of the glucocorticoid:CBG complex, allowing glucocorticoid to dissociate from CBG and exert its anti-inflammatory action directly at the inflammation site. Accordingly, administration of glucocorticoid in CBG-bound form is an effective means for localizing glucocorticoid effects to those tissues or sites at which inflammation is active, thus reducing the indiscriminate stimulation of other tissues by glucocorticoids which results in undesirable side effects. Similarly, any anti-inflammatory agent which binds with CBG can be targeted for release specifically at an inflammation site by administering that particular agent in CBG-bound form i.e. as a CBG:anti-inflammatory agent complex.
That CBG is cleaved specifically by leukocyte elastase, a serine protease released locally by neutrophils at sites of inflammation, is particularly remarkable. First, the
region of the CBG molecule that contains the elastase binding site is not well conserved by comparison with another well known elastase substrate, α:-antitrypsin. Moreover, again by analogy with α:-antitrypsin, the elastase cleavage site on CBG involves a neighboring glycosylation site not present at the elastase cleavage site on _.- antitrypsin. Yet, it has now been demonstrated that CBG is indeed cleaved by leucocyte elastase. Moreover, it has been found that steroid binding affinity of CBG is substantially lost following CBG cleavage by leukocyte elastase.
In accordance with the invention, anti-inflammatory agents which bind with CBG are administered in CBG-bound form to treat inflammation in mammals. It should be appreciated that the binding of a particular anti- inflammatory and CBG is mediated by the affinity of one molecule for the other and not through a physical link such as a covalent bond or chemical linking agent. The degree of affinity between CBG and the selected anti-inflammatory agent should be sufficient to enable CBG and the anti- inflammatory agent to remain in association following administration thereof to the mammal to be treated, and allow the agent to dissociate following elastase-induced cleavage of CBG at an inflammation site.
Anti-inflammatory agents suitable for use in the present invention may be identified by screening anti- inflammatory agents in a CBG-binding assay and selecting those having suitable CBG-binding affinity. In general, an anti-inflammatory agent having a CBG affinity constant (dissociation rate, Kd) within the range from 0.1 to 10 nanomolar at about 4'C and physiological pH is suitable for use with CBG according to the present invention. A protocol for screening anti-inflammatory agents for suitability in the present context is described by Mickelson et al. , supra, incorporated herein by reference, which allows the binding affinity of a selected steroid for CBG to be compared with the affinity of human CBG for one of its natural ligands,
cortisol. Any anti-inflammatory agent having CBG human binding affinity which approximates that of cortisol (0.7 nanomolar under the conditions noted above) is preferred for use in accordance with the present invention. Mickelson et al., supra. also identify some criteria useful in predicting whether a particular steroid will be capable of binding adequately with human CBG such as the presence of a 3-oxo group and the absence of an 11 α-hydroxy group on the steroid. While these criteria can be useful in determining binding affinity of steroid for human CBG, it should be understood that the determinative measure of suitability of anti-inflammatory agent, whether steroidal in structure or not, is stability of the CBG:selected agent complex, under the conditions noted above. Specific anti-inflammatory agents useful herein include corticosteroids having glucocorticoid activity such as cortisol and other natural, anti-inflammatory ligands of CBG such as corticosterone and cortisone. Synthetic glucocorticoids which exhibit reduced adverse effects on electrolyte balance, such as prednisolone and ethylprednisolone may also be used. By intentional design, however, most other of the currently available synthetic glucocorticoids have only weak CBG binding affinity that renders them inappropriate for use in the present invention. Nevertheless, synthetic corticosteroids developed subsequently or natural corticosteroids discovered hereafter are useful provided, of course, that they exhibit anti- inflammatory activity and an appropriate CBG binding affinity. The anti-inflammatory agent used in the pharmaceutical compositions of the invention should be of pharmaceutical grade. Whereas acid- and base-addition glucocorticoid salts are commonly employed in prior art compositions to enhance solubility of the glucocorticoid, in injectable solutions for example, salt forms of the selected glucocorticoid are not required in the present compositions although they may
be used, if desired. When complexed with CBG, glucocor¬ ticoids are sufficiently soluble in solution in the amounts useful to treat inflammation, although solubilizers standard in the protein formulation art, such as mannitol, may be used.
CBG useful in the composition of the invention is now a well characterized protein, having been identified in human plasma over thirty years ago. It has since been identified in virtually every vertebrate species examined and has been isolated from numerous mammalian species including rabbit, guinea pig, rodent, humans and others (for a review see Brien, Clinical Endocrinology (1981) 14, 193- 212) . For use in the present invention, CBG may be isolated from"serum using techniques now well known in the art. The most practical and efficient of these techniques involve the use of affinity columns in which the immobilized ligand is either a glucocorticoid or a derivative thereof which binds with high affinity to CBG. The preparation of such a column, in which a cortisol derivative is cross-lined on Sepharose, and its use. in isolating CBG are described by
Rosner in J. Steroid Biochem. 1972, _., 531-542. Ari improved method for purifying human CBG from pregnancy serum, in which CBG levels are about 2-fold higher than normal serum, is described by Robinson et al. in J. Endocr. (1985) 104, 259-267, incorporated herein by reference. The procedure entails applying serum to a column in which the ligand is a corticosterone derivative, collecting the CBG-containing eluate and then subjecting the eluate to successive purification steps such as gel electrophoresis and including a step in which contaminating albumin is removed.
Antibodies to CBG have also now been prepared (see Robinson et al. , supra) and may also be used to generate an affinity column useful to isolate CBG from serum.
As an alternative to using CBG isolated from natural sources, the compositions of the present invention may be prepared using recombinant CBG i.e. CBG that is produced by
microbial cells genetically engineered for this purpose. To produce recombinant human CBG, for example, DNA coding for the amino acid sequence thereof, as reported by Hammond et al. in Proc. Natl. Acad. Sci., U.S.A., 84, 5153-5157, August 1987, is incorporated on any of the well-known expression or secretion vectors. The resulting DNA construct is then introduced into the microbial host for which the selected vector is adapted, the host is cultured under conditions conducive to expression of the CBG-encoding DNA and the CBG so produced is recovered, using purification techniques similar to those used to recover naturally occurring CBG.
The CBG-encoding DNA to be incorporated on the selected vector may be obtained using any of a variety of techniques used commonly in the genetic engineering art, such as by synthesis or by isolating cDNA from a human liver or lung cDNA library e.g. in the manner reported by Hammond et al. in INSERM. Vol 149, 113-121, 1986. The CBG-encoding DNA is then incorporated on the expression vector i.e. is linked operably to expression control DNA sequences, including transcription-promoting and terminating sequences and optionally including sequences enabling the CBG product to be secreted to the medium following its expression. Numerous expression vectors are available for use with a variety of microbial hosts, such as bacteria including E. coli. Streαtomyces and Bacillus subtilis and eukaryotes including yeasts such as Saccharomvces and Candida filamentous fungi such as the nidulans, nicer and orvzae species of Asperσillus. and mammalian cell lines such as COS and CHO. Thus, recombinant CBG may be produced using vector systems and protocols already established for use with these hosts.
In general, CBG obtained from any source may be used provided that it has the appropriate binding affinity for the selected glucocorticoid and is susceptible to cleavage by elastase. Since it is conceivable that a CBG:elastase
relationship exists which is specific for a given mammalian species, it is recommended that the administered composition comprises CBG native to the mammalian species, being treated. For example, human CBG is preferably used in compositions administered to treat inflammation in humans, equine CBG is used in compositions intended for treating inflammation in horses, etc. Moreover, the CBG binding affinity of a particular anti-inflammatory agent may vary, depending on the mammalian source of the CBG selected. Accordingly, binding assays of the type described above should be performed in order to select those anti- inflammatory agents most suitable for use in combination with a given CBG species.
To prepare compositions of the invention, the selected anti-in lammatory agent and CBG are simply mixed in solution, such as physiological saline, at pH 7.5, with agitation to generate the required complexes. Formation of CBG:anti-inflammatory agent complexes can be facilitated by incubating the mixture at physiological temperature and pH. It is important, when CBG:glucocorticoid complexes are prepared, to maintain pH above 6, preferably above pH 6.5. The affinity of CBG for glucocorticoid can be reduced below pH 6, and the protein may be irreversibly denatured. It is desirable, in order to achieve the maximum localizing effect conferred by CBG following administration, that the CBG in the administered composition is saturated with glucocorticoid i.e. that the molar ratio of glucocorticoid bound to CBG in the composition is substantially 1:1. To accomplish this, it is preferred to use a molar excess of glucocorticoid such as a molar ratio of from about 1.1:1 to about 5:1 (glucocorticoid:CBG) when generating the complexed material. Unbound glucocorticoid may remain with the complexed material, if desired, and can in fact be advantageous to ensure that saturation of CBG is maintained after administration and equilibration with endogenous steroid.
To formulate CBG-bound glucocorticoid for administration, any of the conventional pharmaceutically acceptable carriers may be used, selection of which depends on the intended mode of administration and is dictated to some extent by the proteinaceous nature of the complexes. Injectable solutions may be prepared by mixing CBG and anti- inflammatory agent in the presence of pharmaceutically acceptable liquid vehicles such as buffered saline and physiological saline. Compositions for topical application may be prepared as creams, lotions or ointments by incorporating the CBG-complexed agents in an appropriate base such as triglycerides. Surface active agents may also be used as may preservatives to prevent microbial growth over prolonged storage periods. Aerosol inhalable formulations of CBG-bound glucocorticoid may also be prepared using propellant and an appropriate liquid vehicle.
The compositions of the invention are useful in pharmaceutical and in veterinary applications to treat a variety of conditions involving inflammation. It will be appreciated that the compositions are particularly better adapted for systemic administration than known compositions comprising free anti-inflammatory agent since CBG-binding thereof is capable, by the limiting of therapeutic action to an inflammation site, of reducing the potential for adverse flucocorticoid effects elsewhere in the body. Because of the effect which CBG has on controlling release of glucocorticoid, for example, it may be used in the present compositions in lower amounts relative to compositions of flucocorticoid per se. to elicit an anti- inflammatory response. When administered systemically as an injectable solution, formulations will comprise glucocorticoid (as CBG-bound glucocorticoid) generally in amounts equal to or less than amounts normally used in treating a particular medical condition. To determine appropriate unit doses for treating particular medical conditions with a selected anti-inflammatory agent.
reference may be made to product monographs or more generally to Pharmacopoeias, such as Martindale, The Extra Pharmacopoeia Ed, J. E. F. Reynolds, The Pharmaceutical Press, London, 1982 (see particularly pp. 446-485) . The compositions of the invention may be used to treat those inflammation-related medical conditions or disorders that are treatable by the anti-inflammatory agents per se. In this connection, reference may be made to The Extra Pharmacopoeia cited above and incorporated herein by reference. For example, administration systemically of CBG- bound anti-inflammatory agent will be useful to treat blood disorders including auto-immune haemolytic anemia, idiopathic thrombocytopenic purpura, arthritis, septicemia, etc. -Local injection may be appropriate to treat collagen and rheumatoid disorders as well as certain connective tissue disorders. In cream, ointment or lotion form, the compositions may be applied to treat inflammation active at exposed areas of the skin. Topical formulations may be applied to open wounds to reduce inflammation. r The administration of aerosols is appropriate for treating adult respiratory distress syndrome, respiratory ailments such as steroid-dependent asthma and interstitial lung disease. In general, administration of the compositions of the invention will be useful to reduce inflammation in areas where the CBG-cσrticosteroid complexes can become exposed, following administration, to the action of leukocyte elastase.
Example 1 - Cleavaσe of CBG of Leucocyte Elastase
Human CBG was purified by affinity chromatography and Blue Sepharose chromatography, as previously described (Robinson et al., (1985) J. Endocrinol. 104:250) . To evaluate the relationship of CBG to various serine proteases, approximately lμg pure CBG was incubated (5 min at 37^C) in 30 mM Tris, pH 7.5 (or pH optimal appropriate for the different serine proteases) , with 20ng human leucocyte elastase (Elastin Products Company, Inc.),
cathepsin G (EPC) , thrombin (Boehringer Mannheim Canada) or plasmin (BMC) . The reaction was terminated by boiling in 5μl SDS-PAGE loading buffer, and then subjected to electrophoresis on a 12%-SDS polyacrylamide gel. After the gel was stained with Coomasie Blue, it was apparent that, under the experimental conditions, a clear .5 kDa reduction in the apparent M of human CBG occurred only after incubation with elastase. *
In order to determine the site of cleavage, CBG and elastase were again incubated under the same conditions. The reaction was "snap frozen" and stored at -70°C until subjected to amino-terminal sequence analysis. The results revealed two CBG fragments: the authentic amino-terminus of mature human CBG (Ferlund and Laurell (1981) J. Steroid Biochem. 14.:545), together with a second sequence which was identified as starting with residue 342 (Thr) in the mature form of human CBG (Hammond et al. (1987) Proc. Natl. Acad. Sci. USA 84.:5153) .
The steroid binding properties of human CBG were also tested using a cortisol binding capacity assay (Hammond and Lahteenmaki (1982) Clin. Chem. Acta 132:101) before and after a standard incubation with elastase, as described above. In this way it could be shown that >95% of the steroid binding activity of human CBG was lost after treatment with elastase, indicating that CBG had substantially lost its binding affinity for the anti- inflammatory agent cortisol following exposure to elastase.
Claims
1. A pharmaceutical composition useful in treating inflammation in a mammal, said composition comprising CBG, an anti-inflammatory agent which binds therewith, and a pharmaceutically acceptable carrier.
2. The composition according to claim 1 wherein the anti-inflammatory agent is present in an amount sufficient to bind substantially all of the CBG in the composition.
3. The composition according to claim 1 wherein said anti-inflammatory agent and said CBG are present in substantially equimolar amounts.
4. The composition according to claim 1 wherein said anti-inflammatory agent is a glucocorticoid.
5. The composition according to claim 4 wherein said glucocorticoid is selected from the group consisting of cortisol, prednisolone and methylprednisolone.
6. A composition according to any preceding claim which is an injectable solution.
7. A composition according to any preceding claim in a form suitable for topical administration.
8. A composition according to any preceding claim which is an aerosol.
9. A pharmaceutical composition useful in treating inflammation in humans, which comprises human CBG, an anti- inflammatory agent which binds therewith and a pharmaceutically acceptable carrier.
10. The composition according to claim 9 wherein said anti-inflammatory agent is cortisol.
11. A method for treating inflammation in a mammal, which comprises administering thereto a pharmaceutical composition comprising CBG-bound anti-inflammatory agent.
12. The method according to claim 11 wherein said CBG and the mammal being treated are of the same species.
13. The method according to claim 11 or claim 12 wherein said anti-inflammatory agent is a glucocorticoid.
1 . The method according to claim 11 or claim 12 wherein said anti-inflammatory agent is selected from among the group consisting of cortisol, prednisolone and methylprednisolone.
15. The method according to any one of claims 11-14 wherein said composition is administered by injection.
16. The method according to any one of claims 11-14 wherein said composition is administered topically.
17. The method according to any one of claims 11-14 wherein said composition is administered by inhalation.
18. The use of CBG in the preparation of a pharmaceutical composition for treating inflammation in mammals.
19. The use of CBG according to claim 18 wherein said CBG is human CBG.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT89906796T ATE103814T1 (en) | 1988-06-09 | 1989-06-08 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF INFLAMMATION. |
DE89906796T DE68914454D1 (en) | 1988-06-09 | 1989-06-08 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN TREATING IGNITIONS. |
EP89906796A EP0418297B1 (en) | 1988-06-09 | 1989-06-08 | Pharmaceutical compositions and use thereof in treating inflammation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US204,356 | 1988-06-09 | ||
US07/204,356 US4997814A (en) | 1988-06-09 | 1988-06-09 | Pharmaceutical compositions and use thereof in treating inflammation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989011859A1 true WO1989011859A1 (en) | 1989-12-14 |
Family
ID=22757584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1989/000638 WO1989011859A1 (en) | 1988-06-09 | 1989-06-08 | Pharmaceutical compositions and use thereof in treating inflammation |
Country Status (7)
Country | Link |
---|---|
US (2) | US4997814A (en) |
EP (1) | EP0418297B1 (en) |
JP (1) | JPH04501104A (en) |
AU (1) | AU628826B2 (en) |
CA (1) | CA1333151C (en) |
DE (1) | DE68914454D1 (en) |
WO (1) | WO1989011859A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022898A1 (en) * | 1993-04-07 | 1994-10-13 | Schering Aktiengesellschaft | New glucocorticoids |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2656944B2 (en) * | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | Aerosolization of protein therapeutics |
US4997814A (en) * | 1988-06-09 | 1991-03-05 | Allelix Biopharmaceuticals, Inc. | Pharmaceutical compositions and use thereof in treating inflammation |
US5086039A (en) * | 1988-06-09 | 1992-02-04 | Allelix Biopharmaceuticals, Inc. | Pharmaceutical compositions and use thereof in treating inflammation |
US5543389A (en) * | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5432080A (en) * | 1992-12-16 | 1995-07-11 | Allelix Biopharmaceuticals Inc. | DNA encoding variants of human corticosteroid binding globulin |
US5588673A (en) * | 1994-02-01 | 1996-12-31 | The Bergquist Company | Membrane switch for use over a steering wheel airbag assembly |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997814A (en) * | 1988-06-09 | 1991-03-05 | Allelix Biopharmaceuticals, Inc. | Pharmaceutical compositions and use thereof in treating inflammation |
US5086039A (en) * | 1988-06-09 | 1992-02-04 | Allelix Biopharmaceuticals, Inc. | Pharmaceutical compositions and use thereof in treating inflammation |
-
1988
- 1988-06-09 US US07/204,356 patent/US4997814A/en not_active Expired - Fee Related
-
1989
- 1989-06-08 AU AU37521/89A patent/AU628826B2/en not_active Ceased
- 1989-06-08 CA CA000602201A patent/CA1333151C/en not_active Expired - Fee Related
- 1989-06-08 DE DE89906796T patent/DE68914454D1/en not_active Expired - Lifetime
- 1989-06-08 JP JP1506177A patent/JPH04501104A/en active Pending
- 1989-06-08 WO PCT/GB1989/000638 patent/WO1989011859A1/en active IP Right Grant
- 1989-06-08 EP EP89906796A patent/EP0418297B1/en not_active Expired - Lifetime
-
1992
- 1992-02-03 US US07/829,954 patent/US5344819A/en not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
CHEMICAL ABSTRACTS, Vol. 95, 1981, (Columbus, Ohio, US), M.M. PUGEAT et al., "Transport of Steroid Hormones: Interaction of 70 Drugs With Testosterone-binding Globulin and Cortico-steroid-binding Globulin in Human Plasma"; & J. CLIN. ENDOCRINOL. METAB., 1981, 53(1), 69-75. * |
FEBS LETTERS, Vol. 113, No. 1, April 1980, ELSEVIER/NORTH HOLLAND BIOMEDICAL PRESS (NL), L. SAVU et al., "Corticosterone Binding Globulin: an Acute Phase 'Negative' Protein in the Rat", pages 102-106. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994022898A1 (en) * | 1993-04-07 | 1994-10-13 | Schering Aktiengesellschaft | New glucocorticoids |
Also Published As
Publication number | Publication date |
---|---|
CA1333151C (en) | 1994-11-22 |
EP0418297B1 (en) | 1994-04-06 |
JPH04501104A (en) | 1992-02-27 |
AU3752189A (en) | 1990-01-05 |
AU628826B2 (en) | 1992-09-24 |
DE68914454D1 (en) | 1994-05-11 |
EP0418297A1 (en) | 1991-03-27 |
US5344819A (en) | 1994-09-06 |
US4997814A (en) | 1991-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5492895A (en) | Inhibitors of thrombosis | |
Price et al. | Molecular cloning of matrix Gla protein: implications for substrate recognition by the vitamin K-dependent gamma-carboxylase. | |
AU593820B2 (en) | Novel polypeptides with a blood coagulation-inhibiting action, processes for their preparation and isolation, their use and agents containing them | |
JPH07508404A (en) | Human/pig hybrid factor VIII | |
JPS60233098A (en) | Anticoagulant novel polypeptide | |
CA2006658C (en) | An anticoagulant substance obtained from urine | |
Hubbard et al. | Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site. | |
JP4147329B2 (en) | Pharmaceutical formulation of corticotropin releasing factor with improved stability in liquid form | |
Meier et al. | Purified human mast cells and basophils release human elastase and cathepsin G by an IgE-mediated mechanism | |
EP0418297B1 (en) | Pharmaceutical compositions and use thereof in treating inflammation | |
JP2764264B2 (en) | Fibrinolytic activity enhancer | |
EP0382451A2 (en) | Viper venom Polypeptides and variants | |
HU205145B (en) | Process for producing new superactive insulin analogs and pharmaceutical compositions comprising same as active ingredient | |
Takahashi et al. | Soluble thrombomodulin purified from human urine exhibits a potent anticoagulant effect in vitro and in vivo | |
Liu et al. | Pulmonary biotransformation of insulin in rat and rabbit | |
Braun et al. | Preparation and characterization of proteolyzed forms of human α-thrombin | |
US5086039A (en) | Pharmaceutical compositions and use thereof in treating inflammation | |
Martin et al. | Synthesis and characterization of wild-type and variant. gamma.-carboxyglutamic acid-containing domains of factor VII | |
Higashimori et al. | Pure human inactive renin: evidence that native inactive renin is prorenin | |
SOEDA et al. | An inhibitor of proline endopeptidase: purification from rat brain and characterization | |
Petraglia et al. | Corticotropin-releasing factor-binding protein: origins and possible functions | |
CA2323077A1 (en) | Method and composition for lowering low density lipoprotein cholesterol | |
JPH0782172A (en) | Wound healing agent | |
Weiler et al. | Synthesis and characterization of a bioactive 82-residue sphingolipid activator protein, saposin C | |
Brush | Purification and characterization of inhibitors of insulin specific protease in human serum |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989906796 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1989906796 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1989906796 Country of ref document: EP |